GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CEN Biotech Inc (OTCPK:CENBF) » Definitions » Degree of Financial Leverage

CEN Biotech (CEN Biotech) Degree of Financial Leverage : 0.00 (As of Mar. 2023)


View and export this data going back to 2016. Start your Free Trial

What is CEN Biotech Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). CEN Biotech's Degree of Financial Leverage for the quarter that ended in Mar. 2023 was 0.00. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for CEN Biotech's Degree of Financial Leverage or its related term are showing as below:

CENBF's Degree of Financial Leverage is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.97
* Ranked among companies with meaningful Degree of Financial Leverage only.

CEN Biotech Degree of Financial Leverage Historical Data

The historical data trend for CEN Biotech's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CEN Biotech Degree of Financial Leverage Chart

CEN Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Degree of Financial Leverage
Get a 7-Day Free Trial Premium Member Only 1.17 0.60 0.40 0.60 0.86

CEN Biotech Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Degree of Financial Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.59 0.58 0.62 0.86 0.67

Competitive Comparison of CEN Biotech's Degree of Financial Leverage

For the Drug Manufacturers - Specialty & Generic subindustry, CEN Biotech's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CEN Biotech's Degree of Financial Leverage Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CEN Biotech's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where CEN Biotech's Degree of Financial Leverage falls into.



CEN Biotech Degree of Financial Leverage Calculation

CEN Biotech's Degree of Financial Leverage for the quarter that ended in Mar. 2023 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( -0.037 (Mar. 2023) / -0.096 (Mar. 2022) - 1 )/( -1.47 (Mar. 2023) / -17.86 (Mar. 2022) - 1 )
=-0.6146/-0.9177
=0.67***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


CEN Biotech  (OTCPK:CENBF) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


CEN Biotech Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of CEN Biotech's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


CEN Biotech (CEN Biotech) Business Description

Traded in Other Exchanges
N/A
Address
3295 Quality Way, Suite 300, Windsor, ON, CAN, N8T 3R9
Website
CEN Biotech Inc is an early-stage Canadian biopharmaceutical company. The Company grows, sells, and delivers pharmaceutical-grade medical marijuana to patients.
Executives
Lawrence Lehoux director, officer: Chief Technology Officer 11879 SOLOMAN ST, WINDSOR A6 N8P 1P1
Jeffery Allen Thomas director 23772 WEST ROAD #152, BROWNSTOWN TOWNSHIP MI 48183
Rick Leigh Purdy director 9 ELAINE STREET, ST. ALBERT A0 T8N7R6
Usamakh Saadikh director 3 DRUDBGY NARODOV SQUARE, KYIV 2H 04210
Joseph A. Byrne director, officer: Chief Executive Officer 6 CAMERON SIDE ROAD EAST, ESSEX A6 N8M 2X5
Alex Tarrabain director 18908 89 AVENUE, EDMONTON A0 T5T 6B7
Donald Strilchuck director 352 RIDEAU PL, TECUMSEH A6 N8N 3N9
Richard Boswell director, 10 percent owner, officer: CFO Senior Executive VP 2408 EASTERN AVE., ROCHESTER HILLS MI 48307
Ameen Ferris director 30 AYRSHIRE COURT, BRAMPTON A6 L6Z 0G6
Brian Payne director, officer: Vice President 1027 HUNTINGTON BLVD, BELLE RIVER A6 N0R 1A0
Aubrey De Lavenu Harold Andre director APT 627 VALE DO LOBO, ALMANCIL S1 8135-034
Bahige B. Chaaban director, 10 percent owner, officer: Chief Executive Officer 888 OLD TECUMSAH RD., BELLE RIVER A6 N0R 1A0

CEN Biotech (CEN Biotech) Headlines